Sanofi out­lines big API plans as coro­n­avirus out­break re­port­ed­ly threat­ens short­age of 150 drugs

As the world be­comes in­creas­ing­ly de­pen­dant on Asia for the in­gre­di­ents of its med­i­cines, Sanofi sees busi­ness to be done in Eu­rope.

The French drug­mak­er said it’s cre­at­ing the world’s sec­ond largest ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (API) man­u­fac­tur­er by spin­ning out its six cur­rent sites in­to a stand­alone com­pa­ny: Brin­disi (Italy), Frank­furt Chem­istry (Ger­many), Haver­hill (UK), St Aubin les El­beuf (France), Újpest (Hun­gary) and Ver­to­laye (France). They have mapped out €1 bil­lion in ex­pect­ed sales by 2022 and 3,100 em­ploy­ees for the new op­er­a­tions head­quar­tered in France.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER